Cited by — Neoadjuvant Anlotinib Plus Paclitaxel–Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single‐Arm Phase II Study | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Neoadjuvant Anlotinib Plus Paclitaxel–Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single‐Arm Phase II Study.
No admitted local citation edges point to this work yet.
